INBS INTELLIGENT BIO SOLUTIONS INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1725430 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY57.2%
TTM net income YoY-11.4%
TTM EPS YoY74.6%
Revenue 3-yr CAGR27.6%
Net income 3-yr CAGR—
Margins
Gross margin50.9%
Operating margin-272.2%
Net margin-269.3%
FCF margin—
EBITDA margin-246.5%
Returns
ROE-216.1%
ROA-102.3%
ROIC (approx.)-534.9%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets46.0%
Debt / equity0.00x
Current ratio1.98x
Interest coverage-187.68x
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.22M | $3.05M | $3.11M | $1.26M | $437,146 |
| Cost of revenue | $2.17M | $1.81M | $1.69M | $930,204 | — |
| Gross profit | $2.05M | $1.25M | $1.43M | $326,668 | — |
| SG&A expense | $10.50M | $8.92M | $9.26M | $8.03M | $4.92M |
| Operating income | -$12.61M | -$10.68M | -$10.28M | -$12.60M | -$8.34M |
| Interest expense | $10,736 | $26,339 | $167,140 | — | — |
| Net income | -$12.43M | -$10.57M | -$10.16M | -$10.63M | -$8.31M |
| EBITDA | -$11.44M | -$9.47M | -$9.31M | -$11.78M | -$8.34M |
| EPS (basic) | -8.44 | -20.04 | -6.38 | -127.00 | -11.33 |
| EPS (diluted) | -8.44 | -20.04 | -6.38 | -127.00 | -11.33 |
| Weighted avg. shares (diluted) | 1.47M | 527,364 | 1.59M | 83,717 | 733,263 |
| Balance sheet | |||||
| Cash & equivalents | $3.99M | $1.02M | $6.30M | $1.54M | $8.24M |
| Receivables | $848,464 | $594,614 | $429,704 | $293,861 | — |
| Inventory | $418,577 | $635,215 | $777,537 | $979,907 | — |
| Current assets | $7.10M | $4.14M | $8.53M | $3.86M | $10.87M |
| PP&E, net | $294,399 | $251,325 | $565,850 | $690,175 | $391,408 |
| Intangibles | $2.80M | $3.79M | $4.37M | $5.26M | — |
| Total assets | $11.94M | $8.25M | $13.78M | $10.35M | $12.35M |
| Current liabilities | $4.93M | $5.35M | $5.45M | $5.88M | $4.66M |
| Total liabilities | $6.65M | $5.44M | $5.60M | $6.67M | $5.81M |
| Shareholders' equity | $5.51M | $3.00M | $8.33M | $3.80M | $6.62M |
| Shares outstanding | 2.91M | 732,327 | 3.46M | 194,200 | 744,496 |
| Cash flow statement | |||||
| Operating cash flow | -$11.93M | -$9.68M | -$9.57M | -$7.38M | -$3.36M |
| Capital expenditure | $125,731 | $231,838 | $221,426 | — | — |
| Free cash flow | -$12.05M | -$9.91M | -$9.79M | — | — |
| Investing cash flow | -$85,573 | -$231,838 | -$221,426 | -$694,142 | -$880,221 |
| Financing cash flow | $14.98M | $4.60M | $14.56M | $1.44M | — |
| Depreciation & amortization | $1.16M | $1.21M | $974,355 | $814,481 | $0 |
| Stock-based compensation | $195,208 | $238,045 | $230,496 | $260,000 | — |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.